The gut-derived hormone, peptide YY (PYY) reduces food intake and enhances satiety in both humans and animals. Obese individuals also have a deficiency in circulating peptide YY, although whether this is a cause or a consequence of obesity is unclear. Our aims were to determine whether peptide YY (PYY) over-expression may have therapeutic effects for the treatment of obesity by altering energy balance and glucose homeostasis. We generated PYY transgenic mice and measured body weight, food intake, temperature, adiposity, glucose tolerance, circulating hormone and lipid concentrations and hypothalamic neuropeptide levels (neuropeptide Y; proopiomelanocortin, and thyrotropin-releasing hormone) under chow and high-fat feeding and after crossing these mice onto the genetically obese leptin-deficient ob/ob mouse background. PYY transgenic mice were protected against diet-induced obesity in association with increased body temperature (indicative of increased thermogenesis) and sustained expression of thyrotropin-releasing hormone in the paraventricular nucleus of the hypothalamus. Moreover, PYY transgenic mice crossed onto the genetically obese ob/ob background had significantly decreased weight gain and adiposity, reduced serum triglyceride levels and improved glucose tolerance compared to ob/ob controls. There was no effect of PYY transgenic over expression on basal or fastinginduced food intake measured at 11-12 weeks of age. Together, these findings suggest that long-term administration of PYY, PYY-like compounds or agents that stimulate PYY synthesis in vivo can reduce excess adiposity and improve glucose tolerance, possibly via effects on the hypothalamo-pituitary-thyroid axis and thermogenesis.
Introduction
Type 2-diabetes mellitus and its complications are affecting increasing numbers of people at alarmingly younger ages. This is exacerbated by the current epidemic of obesity, a major risk factor for type 2-diabetes. Although weight loss in overweight or obese individuals significantly reduces the risk or severity of type 2 diabetes, currently the most effective treatments for obesity involve surgical interventions that not only pose medical risks and complications, but are also expensive and unfeasible for many, considering these procedures are generally performed on subjects with a body mass index over 35. Investigating the predisposing and protective factors in the etiology of obesity is vital for finding long-term treatments for obesity and reducing the incidence of type 2 diabetes.
Gut-derived hormones have been of major interest as possible targets for the treatment of obesity in light of their marked effects on satiety and food intake. One of these hormones is peptide YY (PYY), which belongs to a family of peptides including neuropeptide Y (NPY) and pancreatic polypeptide (PP), all of which are known to have potent effects on feeding and energy balance via their unique interactions with G-protein-coupled Y receptors (Y1, Y2, Y4, Y5, y6) (Blomqvist and Herzog, 1997 , Stanley et al., 1986 and Ueno et al., 1999 .
PYY is predominantly produced by endocrine L cells of the lower gastrointestinal tract and is also expressed in alpha cells of the islets of Langerhans as well as in the stomach and brainstem (Pieribone et al., 1992) . Two forms of PYY exist in the circulation: the full length PYY1-36, and the shortened form PYY3-36, cleaved from secreted PYY1-36 by the cell surface enzyme dipeptidyl peptidase IV (Lundberg et al., 1982) . PYY1-36 binds to all known Y receptors, albeit to each with differing affinities, whereas PYY3-36 preferentially binds the Y2 receptor and to a lesser extent the Y5 receptor (Blomqvist and Herzog, 1997) . Obese subjects have significantly reduced circulating levels of PYY (Batterham et al., 2003) . Moreover, it has been suggested that this is due to a deficiency in PYY release from the colon (Le Roux et al., 2005) . In light of these observations, and considering that low fasting serum PYY levels are seen in non-obese subjects with a high genetic predisposition towards subsequent development of obesity on account of a family history of type 2 diabetes mellitus (Boey et al., 2006a) , it is likely that low levels of circulating PYY may not simply be a consequence of obesity but a predisposing factor to the development of obesity.
Recent studies have demonstrated acute affects of PYY1-36 and PYY3-36 in inhibiting food intake in animals and in man (Adams et al., 2004 , Batterham et al., 2002 , Challis et al., 2003 , Chelikani et al., 2004 , Chelikani et al., 2005 , Halatchev et al., 2004 and Riediger et al., 2004 . It is thought that after a meal, PYY3-36, the main form of PYY circulating postprandially, acts on the arcuate nucleus of the hypothalamus. Specifically, PYY3-36 binds to Y2 receptors on NPY neurones, thereby inhibiting the orexigenic effect of these neurons and indirectly stimulating the action of anorexigenic neurons producing POMC (proopiomelanocortin, the precursor to the anorexigenic alpha melanocyte stimulating hormone) (Batterham et al., 2002) . In contrast, other work has suggested that PYY3-36 not only acts via Y2 receptors to inhibit NPY neurones but also directly inhibits POMC neurones via Y2 receptors (Acuna-Goycolea and van den Pol, 2005 and Fetissov et al., 2004) . In light of these findings, it has been proposed that the PYY3-36-mediated inhibition of food intake occurs primarily through the inhibition of NPY neurones. Other studies also show that intraperitoneally injected PYY3-36 activates neurones in the area postrema and nucleus tractus solitarius in rodents, which may be another mechanism by which PYY3-36 influences food intake (Bonaz et al., 1993 and Cone, 2005) .
PYY appears to play a long-term role in regulating food intake, body weight and body composition. A four-week continuous infusion of PYY3-36 in diet-induced obese mice reduced cumulative food intake, weight gain and adiposity (Pittner et al., 2004) . In ob/ob mice and fa/fa rats, on the other hand, four-week continuous infusion of PYY3-36 decreased body weight gain in association with a transient reduction in food intake observed during the first 4 days of infusion only ( Pittner et al., 2004) . These findings suggest that PYY may also influence body weight and body composition via effects independent of changes in food intake. Indeed, seven day subcutaneous administration of PYY3-36 to diet-induced obese mice transiently reduced food intake and also led to maintenance of mass-specific energy expenditure despite concurrent anorexia, reduced respiratory quotient (indicating increased fat oxidation) and led to significantly decreased adiposity (Adams et al., 2006) . Moreover, we and others have previously shown that PYY ablation results in obesity in mice ( Batterham et al., 2006 and Boey et al., 2006b) .
Collectively, these studies suggest that PYY plays a major role in influencing longterm energy balance via effects on food intake and possibly also on metabolic processes, and that long-term elevation of PYY levels may attenuate obesity. However, studies investigating the effects of PYY administration have been limited to a maximum of 4-week duration, which is also not representative of PYY secretion in vivo. Furthermore, the mechanisms underlying PYY-induced effects on food intake, metabolic rate, body weight and adiposity have not yet been elucidated. Answers to these caveats are of relevance to human health since pharmacological treatments for obesity are administered for months, not weeks, and because new obesity treatments may involve enhancing endogenous PYY release with meals or episodic dosing strategies.
In order to test the hypothesis that elevated PYY might result in long-term reductions in food intake, body weight and adiposity, we generated PYY transgenic mice to over-express murine PYY. These mice were studied under chow fed conditions as well as under diet-and genetically induced obesogenic conditions to determine whether long-term endogenous PYY over-expression may have an anti-obesity effect. Moreover, we aimed to elucidate mechanisms for any possible effects of PYY over-expression on energy homeostasis by investigating thermogenesis, the hypothalamo-pituitary-thyroid axis as well as glucose homeostasis.
Research design and methods

PYY transgenic mouse generation
All research and animal care procedures were approved by the Garvan Institute/St. Vincent's Hospital Animal Experimentation Ethics Committee. A 129/SvJ mouse genomic BAC clone containing the PYY gene and flanking sequences was obtained from Prof. Dominic Withers (UCL, UK). The 130 kb clone was mapped and various fragments subcloned. A 10.5 kb SpeI fragment containing 6 kb 5′-flanking sequence, the entire PYY gene and 3 kb 3′-flanking sequence was chosen as the transgene construct (Fig. 1A) . In order to identify the transgene the NsiI restrictions site in the position 9832 of the SpeI fragment was mutated to a BglII restriction site. A 300 bp probe for screening located between nucleotides 7470 and 7770 of the SpeI fragment was generated by PCR. Purified DNA of the modified SpeI fragment was injected into oozytes from C57BL/6 mice and reintroduced into pseudo-pregnant mice. Southern analysis of DNA obtained from tail tips of offspring from these mice revealed two positive founders carrying the PYY transgene. Wild type C57/BL6 mice were used as controls (Animal Resource Centre, Perth, Australia).
Mice genotype was confirmed on DNA obtained from tail tips with PCR using the combination of oligonucleotides mPYY-R (5′-GGTACAAGTATGTGTAGGTGC-3′) and mPYY-S (5′-GAACTCACTCTGTAGACCAG-3′). The conditions for all PCR analyses were 35 cycles of 94 °C for 45 s, 58 °C for 1 min and 63 °C for 1 min. Insertion of the Bgl2 site was confirmed by digesting the PCR product overnight with restriction enzyme Bgl2. Mice genotype was also confirmed by Southern blot analysis of Bgl2 digested DNA employing a probe generated by PCR using oligonucleotidess mPYY-G (5′-GAATTCCCTGTAATGCTG-3′) and mPYY-H (5′-CCCTCCAAGACCTAGGAAA-3′). All of the mice used in experiments were shown by both PCR and Southern blot analysis to carry the PYY transgene.
PYY transgenic mice were also crossed onto mice of mixed C57BL/6/129/SvJ background, heterozygous for the ob/ob gene (Jackson Laboratories, ME, USA). Homozygosity of the ob locus in ob/ob mice was confirmed using PCR with oligonucleotides mOb-2 (5′-GAGTCAAGCATTGTGGAGT-3′) and mOb-3 (5′-CAGTCGGTATCCGCCAAG-3′) using 35 cycles of 94 °C for 45 s, 61 °C for 1 min and 72 °C for 25 s followed by digestion with the restriction enzyme Ddel (Roche Diagnostics, Mannheim, Germany) at 37 °C overnight.
Staining and measurement of PYY positive cells
Whole pancreas and segments of the colon were fixed and stained for PYY as described previously (Boey et al., 2006b ). Six to eight random pancreatic sections obtained from whole pancreas from four male wild type and 4 PYY transgenic mice were stained for PYY. Briefly, tissues fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4 °C were transferred to 70% ethanol before being processed and embedded in paraffin. Sections (7 µm) were cut and mounted onto charged slides. Sections were deparaffinised in xylene restriction site. A 300 bp probe for screening located between nucleotides 7470 and 7770 of the SpeI fragment was generated by PCR. Purified DNA of the modified SpeI fragment was injected into oozytes from C57BL/6 mice and reintroduced into pseudo-pregnant mice. Southern analysis of DNA obtained from tail tips of offspring from these mice revealed two positive founders carrying the PYY transgene. Wild type C57/BL6 mice were used as controls (Animal Resource Centre, Perth, Australia).
PYY transgenic mice were also crossed onto mice of mixed C57BL/6/129/SvJ background, heterozygous for the ob/ob gene (Jackson Laboratories, ME, USA). Homozygosity of the ob locus in ob/ob mice was confirmed using PCR with oligonucleotides mOb-2 (5 0 -GAG-TCAAGCATTGTGGAGT-3 0 ) and mOb-3 (5 0 -CAG-TCGGTATCCGCCAAG-3 0 ) using 35 cycles of 94°C for 45 s, 61°C for 1 min and 72°C for 25 s followed by digestion with the restriction enzyme Ddel (Roche Diagnostics, Mannheim, Germany) at 37°C overnight. 2.3. Reverse transcriptase PCR Whole mouse colon rapidly excised from animals killed by cervical dislocation at 10:00-12:00 h was cleaned and immediately frozen in liquid nitrogen. Total RNA was extracted using Trizol (Invitrogen, CA, USA) according to the manufacturer's instructions. RNA was treated with DNase (Promega, Madison, USA) prior to RNeasy Mini clean-up (Qiagen, Victoria, Australia) following the manufacturers protocol. RNA quality and concentration was determined using the Agilent 2100 bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
Total RNA (1 µg) was denatured at 65 °C for 5 min in the presence of 1 µl oligo(dT) 20 and 1 µl dNTP, and cDNA was synthesized according to the manufacturers instructions (Invitrogen, CA, USA).
GAPDH and PYY expression were determined using RT-PCR. In brief, a 25 µl PCR reaction volume containing cDNA (1 µl), 0.25 µl primers for GAPDH (Forward 5′ ACTTTGTCAAGCTCATTTCC 3′; Reverse 5′ TGCAGCGAACTTTATTGATG 3′) or PYY (Forward 5′ ACGGTCGCAATGCTGCTAAT 3′; Reverse 5′ AAGGGGAGGTTCTCGCTGTC) (100 pmol/µl), 2.5 µl 10xPCR Buffer, 3 µl MgCl 2 , 0.25 µl dNTPs (25 mM), 0.5 µl Taq polymerase (Roche Diagnostics, Castle Hill, NSW) made up to 25 µl with water was reacted using conditions starting with 94 °C for 5 min followed by the optimized conditions (GAPDH: 94 °C for 40 s, 57 °C 40 s, 72 °C 45 s, 25 cycles; PYY: 94 °C for 40 s, 65 °C 40 s, 72 °C 45 s, 30 cycles).
Measurement of food intake and bodyweight
Male C57/BL6 wild type, PYYtg, ob/ob (a gift from M. Cleasby, Garvan Institute, Sydney Australia) and PYYtg/ob animals originating from three to four different breeding pairs were housed under conditions of controlled temperature (22 °C) and illumination (12 h light cycle, lights on at 07:00 h) (n = 6-12). Unless otherwise stated, all mice were fed a normal chow diet ad libitum (6% calories from fat, 21% calories from protein, 71% calories from carbohydrate, 2.6 kcal/g, Gordon's Speciality Stock Feeds, Yanderra, NSW, Australia). One group of wild type and PYYtg mice were fed a high fat diet (46% calories from fat, 21% calories from protein, 33% calories from carbohydrate, 4.72 kcal/g) from 4 to 5 weeks of age onwards. The high fat diet, made in-house, was based on the composition of Rodent Diet Catalogue Number D12451 (Research Diets, New Brunswick, NJ), with the exception that safflower oil and copha were used in place of soybean oil and lard, respectively. Body weight was monitored weekly. At 11 weeks of age, non-fasted food and water intake were measured over four consecutive days in individually housed mice. Actual food intake was calculated as the weight of pellets taken from the food hopper minus the weight of food spilled in the cage. The weight of spilled food was determined as the 24-h increase in weight of the cage bedding, after removing all feces and air-drying to eliminate weight changes due to urine and water bottle drips. At 12 weeks of age, mice were fasted for 24 h and the amount of food removed from the hopper was measured at 1, 2, 8, 24, 48 and 72 h after re-introduction of food. Actual food intake was determined as described above after 24, 48 and 72 h of refeeding, and body weight was tracked at the same time each day before and after the 24-h fast.
Temperature measurements
Rectal temperature was measured at 16:00 h for 3 days consecutively in 10-week-old mice. PYYtg and wild type mice were placed in a hinged restraining cylinder and a rectal temperature probe (Physitemp Instruments, NJ, USA) attached to the BAT-10 Multipurpose Thermometer (Physitemp Instruments, NJ, USA) was inserted and left in place until the temperature reading stabilized. Temperatures were measured in PYYtg/ob and ob/ob mice without a hinged restraining cylinder due to size.
Glucose tolerance tests
At 13 weeks of age, mice were fasted for 24 h prior to intraperitoneal glucose tolerance tests (1 g/kg). Serial blood samples were collected from the tail for determination of serum glucose and insulin levels. Area under the curve (AUC) was calculated between 0 and 120 min after glucose injection and expressed as mM glucose per minute.
Tissue collection and analysis
Wild type, PYYtg, ob/ob and PYYtg/ob mice (16 weeks of age) were killed by cervical dislocation and decapitation between 12:00 and 14:00 h for collection of trunk blood. Brains were immediately removed and frozen on dry ice. White adipose tissue depots (right inguinal, right epididymal or periovarian (gonadal), right retroperitoneal and mesenteric) were removed and weighed.
Serum analyses
Total serum PYY concentrations were determined using a radioimmunoassay kit from Phoenix Pharmaceuticals, Belmont, CA, USA as previously described (Boey et al., 2006a) . Serum glucagon levels were measured by radioimmunoassay kits from Linco Research (St. Louis, MO, USA), insulin levels were measured using an ELISA Kit from Mercodia (Uppsala, Sweden) or Linco Research, serum free T4 and testosterone concentrations were measured with kits from ICN Biomedicals (Costa Mesa, CA, USA), serum IGF-1 was determined using an RIA Kit from Bioclone (Marrickville, NSW, Australia), serum glucose was determined with a glucose oxidase assay kit (Trace Scientific, Melbourne, Australia), and serum triglyceride and free fatty acid levels were determined with kits from Roche Diagnostics, Mannheim, Germany and Wako, Osaka, Japan, respectively.
2.9.
In situ hybridization Coronal brain sections (20 µm) were cut on a cryostat (Leica CM3050S, Leica, Wetzlar, Germany) and thaw-mounted on Superfrost® slides (Menzel-Glaser, Braunschweig, Germany). Matching sections from the same coronal brain area of PYY transgenic and wild type mice (five mice per group) were assayed together using DNA oligonucleotides complementary to mouse NPY (5′-GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTA-CCTAGCAT-3′); mouse POMC (5′-TGGCTGCTCTCCAGGCACCAGCTCCACACATCTA-TGGAGG-3′); and mouse thyrotropin-releasing hormone (TRH; 5′-AACCTTACTCCTCCA-GAGGTT CCCTGACCCAGGCTTCCAGTTGTG-3′) as described previously (Sainsbury et al., 2002) . NPY and POMC expression were determined in the arcuate nucleus and TRH was determined in the paraventricular nucleus of the hypothalamus.
For evaluation of mRNA levels in scattered neurons, images from dipped sections were digitized using a ProgRes 3008 camera (Zeiss, Jena, Germany) mounted on a Zeiss Axiophot microscope. Silver grain density over single neurons was evaluated using NIHImage 1.61 software (written by Wayne Rasband and available at zippy.nimh.nih.gov). Background labeling was uniform and never exceeded 5% of specific signal.
Statistical analyses
Analyses were done using two-factor ANOVA to assess differences due to genotype and diet. When the effect of genotype was significant, or when there was a significant genotype-diet interaction effect, Fisher's post hoc tests were used to determine differences amongst groups. Results for body weight, lean and fat mass, food intake and differences in serum glucose and insulin levels during glucose tolerance tests were compared among groups using two-factor repeated measures ANOVA followed by Fisher's post hoc tests. StatView version 4.5 (Abacus Concepts Inc., CA, USA) was used for all statistical analyses and p < 0.05 was accepted as being statistically significant.
Results
Increased embryonic lethality in PYY transgenic mice
Of the 150 offspring derived from oozytes injected with a construct containing the murine PYY gene under its endogenous mouse promoter, only two mice carrying the PYY transgene were identified by southern blot analyses ( Fig. 1B) . The low success rate in obtaining PYY over-expressing mice suggests that strong expression of PYY may be embryonic lethal, which has been confirmed by a recent report that CMV driven PYY overexpression in embryonic life leads to neural tube defects (Yuzuriha et al., 2007) . RT-PCR confirmed the over-expression of PYY mRNA in our PYY transgenic mice (Fig. 1C) . Serum concentrations of PYY were elevated in fat-fed transgenic mice (40.6 ± 5.9 pM versus 24.4 ± 2.8 pM in fat-fed wild types, means ± SEM of 3-5 mice per group), albeit this difference did not reach statistical significance. Nevertheless, quantification of alpha cells in the islets of Langerhan, known to produce PYY (Lundberg et al., 1982) , clearly demonstrated that under conditions of high-fat feeding, the number of PYY-positive alpha cells in the islets of Langerhans was significantly higher in PYY transgenic mice compared to wild type mice (Table 1 ). In this regard it is noteworthy that high-fat feeding increases alpha cell size, volume and number (Cerf et al., 2005) .
Attenuated diet-induced obesity in PYYtg mice with no effects on food intake
There has been controversy as to whether exogenously administered PYY reduces food intake in mice (Tschop et al., 2004) . Moreover, there have been limitations in elevating PYY levels using osmotic mini-pumps because this mode of administration does not mimic the secretion of PYY in vivo ( Pittner et al., 2004) . We therefore investigated food intake as well as body weight and adiposity in PYYtg mice. Under chow feeding, body weight ( Fig. 2A) , basal and fasting-induced food intake measured at 11-12 weeks of age (Table 1 , Fig. 3A ) and adiposity ( Fig. 2D and F) were comparable between wild type and PYY transgenic animals. Interestingly, under high-fat feeding PYY transgenic mice showed no significant difference in body weight (Fig. 2B ) but were significantly less fat ( Fig. 2D and F) and had a significantly higher body temperature (Fig. 2H ) than fat-fed wild types in the absence of changes in basal or fasting-induced food intake measured at 11-12 weeks of age (Table 1 , Fig. 3B ). This increase in temperature suggests that the reduced adiposity observed in highfat fed PYY transgenic compared to fat-fed wild type mice was attributed by an increase in thermogenesis. In keeping with their lack of change in food intake compared to wild type values, PYYtg mice were no different from wild types with respect to water intake ( Table 1) . High fat-fed PYYtg mice lost significantly less body weight than controls after a 24-h fast compared to wild type ( Fig. 3D ).
Increased activity of the hypothalamo-pituitary-thyroid axis in PYY transgenic mice
In order to determine whether the decreased fat mass in PYYtg mice was accompanied by changes in circulating lipids, free fatty acid and triglyceride levels in PYY transgenic animals on a high-fat diet were analysed. PYYtg mice exhibited significantly lower serum free fatty acid and triglyceride levels in comparison with transgenic animals on a chow diet ( Table 1) , although chow-fed PYY transgenics on a lean background had higher serum free fatty acid and triglyceride levels than chow-fed wild type controls (Table 1) . Circulating thyroid hormone levels (free T4) were also measured as an indication of activity of the hypothalamo-pituitary-thyroid axis, an important regulator of thermogenesis and metabolic rate (Ribeiro et al., 2001) . Unlike wild type animals, which showed significantly higher serum free T4 levels on a high-fat diet compared to a chow diet, no such increase in circulating free T4 levels was seen in transgenic mice with high fat feeding (Table 1 ). There were no differences in serum concentrations of glucagon, testosterone, glucose or insulin between wild type and PYYtg animals under conditions of chow-or high fat feeding ( Table 1) . Interestingly, under chow-fed conditions, serum IGF-1 levels were significantly lower in PYYtg animals than in wild types ( Table 1) .
PYY transgenic mice have increased thyrotropin-releasing hormone (TRH) expression in the paraventricular nucleus of the hypothalamus
To assess possible central mechanisms for the decreased adiposity and increased thermogenesis observed in PYYtg mice, we measured central expression of peptides known to regulate energy balance (TRH, NPY and POMC). Under chow-fed conditions, TRH levels in the paraventricular nucleus were similar between PYYtg and wild type animals ( Table 2) . However, although TRH levels were significantly reduced by high-fat feeding in wild type animals, TRH levels in PYY transgenic animals were unaffected by diet and were significantly higher in high-fat fed PYYtg mice compared with high-fat fed wild types ( Table 2) . alpha cells in the islets of Langerhan, known to produce PYY (Lundberg et al., 1982) , clearly demonstrated that under conditions of high-fat feeding, the number of PYY-positive alpha cells in the islets of Langerhans was significantly higher in PYY transgenic mice compared to wild type mice (Table 1 ). In this regard it is noteworthy that high-fat feeding increases alpha cell size, volume and number (Cerf et al., 2005) .
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To assess possible central mechanisms for the decreased adiposity and increased thermogenesis observed in PYYtg mice, we measured central expression of peptides known to regulate energy balance (TRH, NPY and POMC). Under chow-fed conditions, TRH levels in the paraventricular nucleus were similar between PYYtg and wild type animals (Table 2) . However, although TRH levels were significantly reduced by high-fat feeding in wild type animals, TRH levels in PYY transgenic animals were unaffected by diet and were significantly higher in highfat fed PYYtg mice compared with high-fat fed wild types (Table 2) .
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This study demonst in the regulation of en modestly increased ex reduce body weight a genetically-induced ob Under chow-fed conditions, expression of NPY in the arcuate nucleus of the hypothalamus was 16% higher in PYY transgenic mice compared to wild types, albeit the difference was not significant, and there was no change in POMC expression observed between the chow-fed groups (Table 2) . NPY and POMC expression were not different between high-fat fed groups (Table 2) .
3.5. PYY transgenic expression results in decreased body weight and adiposity in leptin deficient mice As PYY transgenic mice were protected against the development of diet-induced obesity, we were interested in determining the effect of PYY over-expression on a genetic model of obesity, using ob/ob mice. PYYtg/ob mice had a significantly lower body weight than ob/ob controls ( Fig. 2C) . Similar to high-fat fed PYYtg mice, PYYtg/ob mice had significantly less white adipose tissue both in absolute terms (data not shown) and as a percent of body weight ( Fig. 2E ) and an increased body temperature (Fig. 2I) than ob/ob controls, in the absence of changes in basal and fasting-induced food intake ( Table 1, Fig. 3C ). Consistent with the lack of effect of the PYY transgene on food intake, water intake of PYYtg/ob mice was no different from that of ob/ob mice ( Table 1) . However, PYYtg/ob mice showed significantly lower serum triglyceride levels than ob/ob controls ( Table 1) , in keeping with the associated decrease in fat mass (Fig. 2E) . This demonstrates that PYYtg mice have reduced weight and body fat via effects independent of food intake.
PYYtg/ob mice exhibit improved glucose tolerance
In light of our previous findings that PYY ablation results in basal and glucoseinduced hyperinsulinemia and glucose intolerance (Boey et al., 2006b) , we hypothesized that PYYtg mice would have improved glucose tolerance. Surprisingly, under conditions of chowand high-fat feeding, fasting serum glucose levels were significantly higher in PYYtg compared to wild type mice ( Fig. 4A and B) . However, serum glucose levels, glucose area under the curve and serum insulin levels during a glucose tolerance test were not significantly different between chow-or fat-fed transgenic and wild type animals on a lean background (Fig. 4A + B , D + E, and G + H).
As PYYtg/ob mice showed decreased body weight and fat mass, we hypothesized that PYY over-expression may have additional beneficial effects on the hypeinsulinemia, hyperglycemia and insulin resistance exhibited by ob/ob mice. In keeping with this, PYYtg/ob mice had significantly lower fasting serum glucose levels and were markedly more glucose tolerant than ob/ob animals during the glucose tolerance test ( Fig.  4C + F) . PYYtg/ob mice also exhibited lower serum insulin levels for the duration of the glucose tolerance test ( Fig. 4I) .
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Notably, chow-fed PYY transgenic animals displayed significantly lower serum IGF-1 levels than wild types, consistent with data from PYY knockout mice which show significantly increased serum IGF-1 levels and increased GHRH mRNA expression in the ventromedial hypothalamus (VMH) ( Boey et al., 2006b) . These data -together with findings that growth hormone and IGF-1 enhance PYY expression ( Gomez et al., 1996 and Wang et al., 2004) support the notion that PYY is involved in a feedback loop to inhibit the somatotropic axis.
PYY transgenic mice showed no significant decrease in basal or fasting-induced food intake when investigated at 11-12 weeks of age. It was recently shown that whereas continuous infusion of PYY3-36 to obese or diabetic rodent models via osmotic mini pumps results in transient reductions in food intake that persist for only 4-6 days (Adams et al., 2006 and Pittner et al., 2004) , intermittent administration of PYY3-36 to lean or diet-induced obese rats results in reductions in food intake that are sustained for the entire 10-21-day study period (Chelikani et al., 2006 and Chelikani et al., 2007) . It is possible that early PYYinduced reductions in food intake and energy balance may induce compensatory responses to help restore energy homeostasis, or that long-term administration of PYY leads to desensitization and downregulation of Y receptors. Therefore it cannot be excluded that our PYY transgenic animals may have had transient reductions in food intake in early life (e.g. before weaning), and that such anorexia may have led to reductions in body weight and/or adiposity that were maintained throughout the study.
The amount of PYY over-expression in our PYY transgenic animals was not as high as anticipated. However, our findings that only two founder animals were produced, one of which died, and the fact that we found a high frequency of fatalities in either gender of our PYYtg breeding pairs indicates that high endogenous PYY expression are disadvantageous during development. Hence, it is likely that only PYY transgenic mice that had modest overexpression of PYY survived. This is supported by a recent study showing that CMV driven PYY over-expression resulted in neural tube defects in mice, a common cause of congenital malformation that leads to infant mortality ( Yuzuriha et al., 2007) . Nonetheless, our studies demonstrate that even the mild increases in PYY expression observed in our PYY transgenic mice were sufficient to induce significant effects on body weight, adiposity, thermogenesis, activity of the hypothalamo-pituitary-thyroid axis, glucose tolerance and IGF-1 levels. Moreover, the fact that many of the phenotypic characteristics observed in our PYYtg mice were opposite to effects seen in PYY −/− mice (e.g. fat mass, serum insulin levels in response to glucose as well as serum IGF-1 levels) provides further support that the phenotype observed in our PYYtg mice is due to PYY over-expression. Increased PYY expression is evident in the pancreatic islets of high-fat fed PYY transgenic animals but not in chow-fed PYY transgenics suggesting that high fat feeding evokes an increase in endogenous PYY production, which may help to explain why the effects of our PYY transgene were more apparent under conditions of high fat feeding. Alternatively, PYY produced in these mice may be rapidly degraded in vivo in compensation for the increased rates of production ( Shechter et al., 2005) .
In summary, we show that PYYtg mice are protected against the development of obesity in high-fat fed and ob/ob mice in the absence of effects on basal-or fasting-induced food intake when measured at 11-12 weeks of age. Similarly, PYYtg/ob mice exhibited decreased bodyweight, fat mass and improved glucose tolerance associated with decreased insulin levels. This is consistent with data from PYY knockout mice generated in our laboratory, which were hyperinsulinemic and became fatter than controls with aging or high fat feeding, in the absence of changes in food intake measured at 11-12 weeks of age ( Boey et al., 2006b ). Additionally, a recent PYY knockout mouse model was also shown to exhibit an obese phenotype, albeit that model also showed significant basal and fasting-induced hyperphagia when measured at 8 weeks of age (Batterham et al., 2006) . Together, our findings support the possibility that measures to increase PYY production and secretion may be therapeutic for the treatment of obesity, not only via effects on appetite regulation but possibly also on energy efficiency.
